4,4-Dimethylazepine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 4,4-Dimethylazepine
• 英文别名: 4,4-dimethylazepine
• 化学式: C₈H₁₁N
• 分子量: 121.18
• InChiKey: PULNFUUKJPBQLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] CONDENSED ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES<br/>[FR] DÉRIVÉS D'ISOXAZOLINE CONDENSÉS ET LEUR UTILISATION COMME HERBICIDES
  申请人：BASF SE

  公开号：WO2021224040A1

  公开（公告）日：2021-11-11

  The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R6 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; W is a bicyclic heterocycle; X is a bond or a divalent unit; Y is hydrogen, cyano, hydroxyl or a linear or cyclic organic group. The invention further refers to a composition comprising such compound and to the use thereof for controlling unwanted vegetation.

  该发明涉及公式（I）的化合物，以及它们作为除草剂的用途。在该公式中，R1到R6代表诸如氢、卤素或有机基团（如烷基、烯基、炔基或烷氧基）等基团；W是一个双环杂环；X是一个键或二价基团；Y是氢、氰基、羟基或线性或环状有机基团。该发明还涉及包含这种化合物的组合物以及将其用于控制不受欢迎的植被。
• [EN] BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY<br/>[FR] COMPOSÉS BICYCLIQUES POUR DIAGNOSTIC ET TRAITEMENT
  申请人：AC IMMUNE SA

  公开号：WO2017153601A1

  公开（公告）日：2017-09-14

  The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

  本发明涉及可以用于诊断、监测疾病进展或监测药物活性的化合物(I)的公式，该化合物可用于与α-突触核蛋白（α-突触核蛋白，A-突触核蛋白，aSynuciein，A-syn，a-syn，aSyn）聚集相关的一组疾病和异常，包括但不限于Lewy小体和/或Lewy神经纤维，如帕金森病。这些化合物特别有助于确定对这种疾病的易感性，监测残留疾病，或预测患有这种疾病的患者对某种药物治疗的反应性。这些化合物还可用于治疗、缓解或预防与α-突触核蛋白聚集相关的疾病或异常。
• BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
  申请人：AC Immune SA

  公开号：EP4001277A2

  公开（公告）日：2022-05-25

  The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

  本发明涉及可用于诊断、监测疾病进展或监测药物活性的新型化合物，这些疾病和异常与α-突触核蛋白（a-synuclein，A-synuclein，aSynuclein，A-syn，α-syn，aSyn）聚集有关，包括但不限于路易体和/或路易神经元，如帕金森病。本化合物尤其适用于确定此类疾病的易感性、监测残余疾病或预测患有此类疾病的患者对某种药物治疗的反应性。本化合物还可用于治疗、缓解或预防与α-突触核蛋白聚集相关的失调或异常。
• ORGANIC ELECTROLUMINESCENT DEVICE
  申请人：LG Display Co., Ltd.

  公开号：EP1603990B1

  公开（公告）日：2018-07-25
• METHODS OF MAKING NANAOSIZED PARTICLES OF BENZOIMIDAZOLONE PIGMENTS
  申请人：Xerox Corporation

  公开号：EP2290013B1

  公开（公告）日：2017-03-29